Literature DB >> 11719311

Follow-up of bronchial precancerous lesions and carcinoma in situ using fluorescence endoscopy.

S Bota1, J B Auliac, C Paris, J Métayer, R Sesboüé, G Nouvet, L Thiberville.   

Abstract

Little is known about the natural history of precancerous bronchial lesions. Histological changes occurring in 416 bronchial intraepithelial lesions (104 high-risk subjects) were assessed over a 2-yr period, using repeated follow-up autofluorescence endoscopies. During the study, 6 of 36 normal epitheliums became dysplastic; 47 of 152 metaplasia evolved to low-grade dysplasia, two progressed to carcinoma in situ, and one to invasive cancer; 6 of 169 low-grade epithelial lesions progressed to a persistent severe dysplasia; 10 of 27 severe dysplastic lesions and 28 of 32 carcinoma in situ persisted or progressed, respectively (p = 0.0005, severe dysplasia versus carcinoma in situ 24 mo outcome). Carcinoma in situ appeared more frequent in patients with a prior history or concomitant cancer (p = 0.003). Persistence of smoking during the study did not influence high-grade lesion outcome. Progression of low-grade epithelial lesions during the study occurred only in patients with at least a high-grade lesion in another site at baseline (9 of 147 lesions, 6.1%). Our study suggests that low-grade epithelial lesions could be safely followed-up at 2 yr in patients without high-grade lesions at baseline, whereas severe dysplasia should be treated if they persist at 3 mo. Immediate treatment of carcinoma in situ appears warranted.

Entities:  

Mesh:

Year:  2001        PMID: 11719311     DOI: 10.1164/ajrccm.164.9.2012147

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  43 in total

Review 1.  Lung cancer . 3: Fluorescence bronchoscopy: clinical dilemmas and research opportunities.

Authors:  A K Banerjee; P H Rabbitts; J George
Journal:  Thorax       Date:  2003-03       Impact factor: 9.139

Review 2.  Sputum examination for early detection of lung cancer.

Authors:  F B J M Thunnissen
Journal:  J Clin Pathol       Date:  2003-11       Impact factor: 3.411

3.  Preinvasive Endobronchial Lesions: Lung Cancer Precursors and Risk Markers?

Authors:  Stephen Lam; Eva Szabo
Journal:  Am J Respir Crit Care Med       Date:  2015-12-15       Impact factor: 21.405

Review 4.  Pathogenesis of lung cancer: 100 year report.

Authors:  York E Miller
Journal:  Am J Respir Cell Mol Biol       Date:  2005-09       Impact factor: 6.914

5.  High-grade lesion: What does it tell us?

Authors:  E S Edell
Journal:  Thorax       Date:  2007-01       Impact factor: 9.139

6.  Bimodality surveillance of high-risk patients for lung cancer.

Authors:  Gordon H Downie
Journal:  Thorax       Date:  2007-04       Impact factor: 9.139

Review 7.  Techniques of endoscopic airway tumor treatment.

Authors:  Nicolas Guibert; Laurent Mhanna; Sylvain Droneau; Gavin Plat; Alain Didier; Julien Mazieres; Christophe Hermant
Journal:  J Thorac Dis       Date:  2016-11       Impact factor: 2.895

8.  Chromosomal aneusomy in bronchial high-grade lesions is associated with invasive lung cancer.

Authors:  Steinn Jonsson; Marileila Varella-Garcia; York E Miller; Holly J Wolf; Tim Byers; Sarah Braudrick; Porntip Kiatsimkul; Marina Lewis; Timothy C Kennedy; Robert L Keith; Johannes Bjornsson; Annette McWilliams; Stephen Lam; Fred R Hirsch; Wilbur A Franklin
Journal:  Am J Respir Crit Care Med       Date:  2007-11-07       Impact factor: 21.405

9.  In vivo optical coherence tomography imaging of preinvasive bronchial lesions.

Authors:  Stephen Lam; Beau Standish; Corisande Baldwin; Annette McWilliams; Jean leRiche; Adi Gazdar; Alex I Vitkin; Victor Yang; Norihiko Ikeda; Calum MacAulay
Journal:  Clin Cancer Res       Date:  2008-04-01       Impact factor: 12.531

10.  Transcriptome profiles of carcinoma-in-situ and invasive non-small cell lung cancer as revealed by SAGE.

Authors:  Kim M Lonergan; Raj Chari; Bradley P Coe; Ian M Wilson; Ming-Sound Tsao; Raymond T Ng; Calum Macaulay; Stephen Lam; Wan L Lam
Journal:  PLoS One       Date:  2010-02-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.